Takeda Pharmaceutical Co Ltd (HAM:TKD)
€ 25.5 -0.16 (-0.62%) Market Cap: 41.10 Bil Enterprise Value: 67.01 Bil PE Ratio: 22.79 PB Ratio: 0.95 GF Score: 75/100

Takeda Pharmaceutical Co Ltd Oncology Focused Investor Call Transcript

Jun 08, 2020 / 12:00PM GMT
Release Date Price: €32.54 (+0.68%)
Unidentified Participant

Hello, everyone, and welcome to Takeda's oncology focused investor call. Before starting I would like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today.

The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice in today's presentation material. I would now like to turn the call over to Costa Saroukos, Chief Financial Officer of Takeda.

Costa Saroukos
Takeda Pharmaceutical Company Limited - CFO

Hello, everyone. This is Costa Saroukos speaking. Thank you for taking the time to join us today. It gives me great pleasure to welcome you to this investor call focusing on Takeda Oncology.

Many of you will have seen our R&D Day in November last year where we gave an overview on how the R&D transformation we initiated five years ago is starting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot